Prescription Drug Supply Chain Pricing Transparency Act
- Bill Number
- S. 3751
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-01-29: Read twice and referred to the Committee on Finance.
- Last Updated
- 2026-02-25T17:40:31Z
AI-Generated Summary
Purpose
The Prescription Drug Supply Chain Pricing Transparency Act (S. 3751) aims to increase understanding of how compensation and payment arrangements tied to prescription drug prices operate within the supply chain, particularly in the Medicare Part D program. It mandates a study by the Government Accountability Office (GAO, an independent agency that audits and evaluates government programs) to examine these structures and report findings to Congress, with the goal of informing potential reforms for greater transparency and fairness in drug pricing.
Key Provisions
- GAO Study Requirements: The Comptroller General (head of the GAO) must conduct a comprehensive study on compensation and payment structures linked to drug prices in the retail prescription drug supply chain. The study covers:
- Types, scale, features (e.g., using drug prices as benchmarks for fees), and frequency of these structures, such as percentage-based fees, among key intermediaries.
- Business models and compensation methods for each intermediary category.
- Differences in these structures between related entities (e.g., those under common ownership) and independent ones.
- Potential conflicts of interest, like how price-based fees might favor higher-priced drugs in selection, distribution, or purchasing.
- Trends over time and across market segments, including Medicare Part D and Medicaid.
- Factors influencing the use of these structures.
- Any other relevant issues identified by the GAO.
- Reporting Timeline: The GAO must submit a report to Congress within 2 years of the bill's enactment, including the study's results and recommendations for new laws or administrative actions.
Significant Changes to Existing Law
This bill amends Section 1860D-42 of the Social Security Act (which governs premiums and related payments in Medicare Part D, the program's coverage for prescription drugs) by adding a new subsection (e). This introduces a one-time study mandate focused on price-related compensation, which was not previously required under this section. No other direct alterations to existing rules are made; the change is limited to requiring analysis rather than imposing new regulations.
Potential Impacts
- On Government Agencies: The GAO will undertake additional workload to complete the study and report, potentially influencing the Centers for Medicare & Medicaid Services (CMS, which administers Part D) through recommended policy changes. Congress may use the findings to adjust drug pricing oversight.
- On Citizens: Medicare Part D beneficiaries (primarily older adults and people with disabilities) could indirectly benefit from greater transparency, which might lead to lower drug costs or fairer pricing if reforms follow. However, immediate effects on individuals are minimal, as the bill only requires a study.
- On International Relations: No direct impacts, as the bill focuses on domestic U.S. prescription drug markets without addressing imports, exports, or foreign entities.
Main Stakeholders Affected
- Intermediaries in the Supply Chain: Pharmacy benefit managers (PBMs, companies that manage drug benefits for insurers), Part D plan sponsors (insurers offering Medicare drug coverage), drug wholesalers, pharmacies, drug manufacturers, pharmacy services administrative organizations (groups that help pharmacies negotiate contracts), brokers/auditors/consultants (advisors on pharmacy benefits), and service providers like rebate aggregators (entities handling drug price discounts).
- Government Entities: GAO (conducting the study), Congress (receiving the report), and CMS (potentially implementing changes).
- Citizens and Patients: Medicare Part D enrollees who pay for prescription drugs, as pricing transparency could affect their out-of-pocket costs.
Notable Legal, Constitutional, or Political Implications
- Legal: The bill enhances oversight of the prescription drug market without creating new enforceable rules, relying instead on GAO's non-binding recommendations. It builds on existing transparency efforts in Medicare law but could set the stage for future regulations addressing antitrust concerns (e.g., conflicts of interest in pricing).
- Constitutional: No apparent issues, as it involves Congress's authority to direct federal agencies like the GAO for studies on public programs, aligning with spending and commerce powers.
- Political: The bipartisan sponsorship (by Senators Bennet and Lankford) signals broad interest in tackling opaque drug pricing practices, which have been criticized for inflating costs. The study could fuel debates on reforming the pharmaceutical industry, potentially leading to legislation curbing percentage-based fees that incentivize higher prices, though it risks pushback from affected businesses.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Sen. Bennet, Michael F. [D-CO]
Cosponsors (1)
Recent Actions
- 2026-01-29: Read twice and referred to the Committee on Finance.
- 2026-01-29: Introduced in Senate
Bill Versions
- Prescription Drug Supply Chain Pricing Transparency Act — issued 2026-01-29 — PDF (5 pages)